Endoxifen
Clinical data | |
---|---|
Trade names | Zonalta |
Other names | 4-Hydroxy-N-desmethyltamoxifen; Desmethylhydroxytamoxifen |
Routes of administration | By mouth |
Identifiers | |
| |
JSmol) | |
| |
|
Endoxifen, also known as 4-hydroxy-N-desmethyltamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group as well as a protein kinase C (PKC) inhibitor. It is under development for the treatment of estrogen receptor-positive breast cancer and for the treatment of mania in bipolar disorder.[1][2] It is taken by mouth.[2]
Endoxifen is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). [3][4][5] The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce endoxifen and afimoxifene (4-hydroxytamoxifen).[6]
Currently, endoxifen is approved by Drugs Controller General of India for the acute treatment of manic episode with or without mixed features of Bipolar I disorder.[7] It is manufactured and sold by Intas Pharmaceuticals under the brand name Zonalta.[8]
Medical uses
Bipolar disorder
Endoxifen is used to treat
Side effects
The most prevalent side effects for endoxifen include headache, vomiting, insomnia. Other side effects were: gastritis, epigastric discomfort, diarrhea, restlessness, somnolence, etc.[8] Some of the adverse events reported with other therapies for the management of manic episodes of bipolar I disorder were not observed during the clinical development program of endoxifen like reduction in platelet count, change in blood thyroid-stimulating hormone levels. There were no deaths, serious or significant adverse events during the conduct of trials. Overall, endoxifen was found to be well-tolerated and safe in patients of bipolar I disorder with acute manic episodes with or without mixed features.[12][10] An important caveat here is that the trial was of very short duration (only three weeks). The long-term safety of Endoxifen has not been established among patients with Bipolar Disorder.
Pharmacology
Pharmacodynamics
Selective estrogen receptor modulator
Endoxifen is a
Protein kinase C inhibition
The exact mechanism by which endoxifen exerts its therapeutic effects has not been established in bipolar I disorder. However, the efficacy of endoxifen could be mediated through protein kinase C (PKC). The PKC represents a family of enzymes highly enriched in the brain, where it plays a major role in regulating both pre-and post-synaptic aspects of neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. The PKC signaling pathway is a target for the actions of two structurally dissimilar antimanic agents – lithium and valproate.[8]
Endoxifen exhibits 4-fold higher potency in inhibiting PKC activity compared to tamoxifen in preclinical studies and is not dependent on the isozyme cytochrome P450 2D6 (CYP2D6) for action on the target tissues.[16]
Pharmacokinetics
Orally administered endoxifen is rapidly absorbed and systemically available. The time to peak (Tmax) is between 4.5 and 6 hours after oral administration. It is not metabolized by cytochrome P450 enzymes. The half-life (t½) life of endoxifen is 52.1 to 58.1 hours.[17]
Research
Endoxifen has been investigated as a potential drug in the treatment of breast cancer.[18][19]
References
- ^ "Z-endoxifen hydrochloride". NCI Drug Dictionary.
- ^ a b "Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals - AdisInsight".
- PMID 23382923.
- Lay summary in: Ericson J (December 12, 2013). "New Breast Cancer Drug Endoxifen Shows Promise In Patients Resistant To Conventional Hormonal Therapy". Medical Daily.
- PMID 19244106.
- PMID 24853369.
- ^ Wilcken N (2016). "Breast cancer: a disease of subtypes". Cancer Forum. 40 (3). Archived from the original on 2016-12-03. Retrieved 2016-11-12.
- ^ a b "List of new drugs approved in the year 2019 till date" (PDF). Central Drugs Standard Control Organisation. 1 October 2021. p. 4.
- ^ a b c "Drug Fact Sheet - Zonalta" (PDF). Intas Pharmaceuticals. 1 October 2021.
- ISBN 978-1-84973-365-6.
- ^ PMID 27346789.
- PMID 19552485.
- ^ S2CID 229688331.
- ^ S2CID 37932.
- ^ PMID 28858267.
- PMID 25258390.
- PMID 20227879.
- S2CID 24590365.
- ISBN 978-1-4649-6344-5.
- PMID 29741509.